William Blair Investment Management LLC Has $298.57 Million Stock Holdings in IDEXX Laboratories, Inc. $IDXX

William Blair Investment Management LLC cut its position in shares of IDEXX Laboratories, Inc. (NASDAQ:IDXX) by 3.9% during the 4th quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The fund owned 441,324 shares of the company’s stock after selling 17,695 shares during the period. IDEXX Laboratories accounts for 0.8% of William Blair Investment Management LLC’s portfolio, making the stock its 16th largest holding. William Blair Investment Management LLC’s holdings in IDEXX Laboratories were worth $298,569,000 at the end of the most recent reporting period.

Several other institutional investors also recently modified their holdings of the company. Prospera Financial Services Inc acquired a new position in shares of IDEXX Laboratories during the 4th quarter worth about $4,188,000. Coldstream Capital Management Inc. boosted its holdings in shares of IDEXX Laboratories by 8.4% during the 4th quarter. Coldstream Capital Management Inc. now owns 1,893 shares of the company’s stock worth $1,281,000 after buying an additional 146 shares during the period. Life Cycle Investment Partners Ltd bought a new stake in shares of IDEXX Laboratories during the 4th quarter worth about $47,915,000. Buckhead Capital Management LLC boosted its holdings in shares of IDEXX Laboratories by 5.9% during the 4th quarter. Buckhead Capital Management LLC now owns 667 shares of the company’s stock worth $451,000 after buying an additional 37 shares during the period. Finally, EverSource Wealth Advisors LLC boosted its holdings in shares of IDEXX Laboratories by 14.8% during the 4th quarter. EverSource Wealth Advisors LLC now owns 713 shares of the company’s stock worth $482,000 after buying an additional 92 shares during the period. 87.84% of the stock is currently owned by institutional investors and hedge funds.

Insider Transactions at IDEXX Laboratories

In other IDEXX Laboratories news, CEO Jonathan Jay Mazelsky sold 23,326 shares of the business’s stock in a transaction dated Thursday, February 26th. The shares were sold at an average price of $657.55, for a total value of $15,338,011.30. Following the completion of the sale, the chief executive officer owned 83,606 shares of the company’s stock, valued at $54,975,125.30. The trade was a 21.81% decrease in their position. The transaction was disclosed in a document filed with the SEC, which is available at the SEC website. Also, EVP Nimrata Hunt sold 1,758 shares of the business’s stock in a transaction dated Tuesday, March 3rd. The shares were sold at an average price of $634.57, for a total transaction of $1,115,574.06. Following the completion of the sale, the executive vice president directly owned 18,141 shares of the company’s stock, valued at $11,511,734.37. This represents a 8.83% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. Insiders sold a total of 27,777 shares of company stock valued at $18,235,113 in the last three months. Insiders own 0.79% of the company’s stock.

IDEXX Laboratories Stock Performance

NASDAQ IDXX opened at $559.37 on Friday. The company has a quick ratio of 0.82, a current ratio of 1.12 and a debt-to-equity ratio of 0.19. The company has a market capitalization of $44.12 billion, a P/E ratio of 41.19, a P/E/G ratio of 3.25 and a beta of 1.58. IDEXX Laboratories, Inc. has a 12-month low of $496.61 and a 12-month high of $769.98. The firm has a 50-day moving average price of $566.51 and a two-hundred day moving average price of $642.70.

IDEXX Laboratories (NASDAQ:IDXX) last posted its quarterly earnings data on Tuesday, May 5th. The company reported $3.47 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $3.41 by $0.06. The firm had revenue of $1.14 billion during the quarter, compared to the consensus estimate of $1.12 billion. IDEXX Laboratories had a net margin of 24.63% and a return on equity of 70.87%. The business’s revenue for the quarter was up 14.3% compared to the same quarter last year. During the same quarter in the previous year, the firm posted $2.91 EPS. IDEXX Laboratories has set its FY 2026 guidance at 14.450-14.900 EPS. Analysts anticipate that IDEXX Laboratories, Inc. will post 14.68 earnings per share for the current year.

Wall Street Analyst Weigh In

IDXX has been the subject of several research analyst reports. Barclays reduced their target price on shares of IDEXX Laboratories from $850.00 to $800.00 and set an “overweight” rating for the company in a report on Thursday, February 5th. Wall Street Zen downgraded shares of IDEXX Laboratories from a “buy” rating to a “hold” rating in a report on Saturday, April 25th. Stifel Nicolaus reduced their target price on shares of IDEXX Laboratories from $775.00 to $675.00 and set a “buy” rating for the company in a report on Tuesday, March 31st. Citigroup initiated coverage on shares of IDEXX Laboratories in a report on Wednesday, April 15th. They set a “neutral” rating and a $650.00 target price for the company. Finally, BTIG Research reduced their target price on shares of IDEXX Laboratories from $830.00 to $800.00 and set a “buy” rating for the company in a report on Tuesday, February 3rd. Seven research analysts have rated the stock with a Buy rating and four have given a Hold rating to the company’s stock. According to MarketBeat, the company presently has an average rating of “Moderate Buy” and a consensus target price of $751.00.

IDEXX Laboratories Profile

IDEXX Laboratories, Inc (NASDAQ: IDXX) is a global developer, manufacturer and provider of diagnostic products and services primarily for the animal health, water testing and food safety markets. Headquartered in Westbrook, Maine, the company supplies in-clinic diagnostic instruments, consumables, reference laboratory testing and practice-management tools that support veterinarians, livestock and dairy producers, and utilities and food producers worldwide.

IDEXX’s product portfolio includes point-of-care tests and immunoassays designed for rapid diagnosis in veterinary clinics, in-clinic chemistry and hematology analyzers, automated urinalysis systems, and digital diagnostic solutions.